Abstract 69P
Background
Colorectal cancer is one of the commonest malignancies worldwide. Next Generation Sequencing (NGS) helps inform treatment pathways for patients post surgery, and also provides valuable information regarding genetic mutations in cancer, the pathogenesis and biology of the disease. We reviewed NGS mutation profiling in our colorectal cancer patients.
Methods
NGS analysis was performed over a 7 year period. Data retrieved from medical records and pathology reports.
Results
92 patients underwent surgery for colorectal cancer during the study period. Mean age: 71 years (Range:44-87). M:F: 1.05:1 43 patients (46.7%) were found to have mutations on NGS sequencing. No significant difference in age, sex, tumour size, lymph node ratio or stage at presentation between the two groups. NGS mutation was significantly associated with right sided disease (p=0.01, Fishers exact test), and this association was highly significant for the BRAF V600e mutation (p=0.0001), NGS mutation was significantly associated with mucinous disease (p=0.04), lymphovascular and / or perineural invasion (p=0.02), and microsatellite instability (p=0.0136), but not metastatic disease at presentation (p=1). Kaplan Meier survival analysis revealed no difference in survival between patients with NGS mutations and those without (p=0.52) or on any subset analysis. COX proportional hazards testing revealed only a significant relationship between tumour size and survival in all patients on multivariate analysis (p=0.002).
Conclusions
NGS sequencing provides relevant information regarding the association of cancers with aggressive features and microsatellite instability. Association of the BRAF mutation with right sided colon cancers has been described previously and may reflect a different pathway to carcinogenesis in the right colon, which has been postulated to have a different origin to the left colon. Significant association of gene mutations with microsatellite instability, but no difference in metastatic disease and overall survival may relect better immune response to these tumours, MSI has been observed to be associated with reduced risk of metastasis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - Development of an exo-miRNA panel for metastasis prediction in breast cancer
Presenter: Shafiqa Siddique
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - Molecular characterization of circulating tumor cells in metastatic breast cancer using shallow whole genome sequencing
Presenter: Michela Bulfoni
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy
Presenter: Marcela Carausu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer
Presenter: Sara Gil-Bernabé
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers
Presenter: Weituo Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Comparative analysis of miRNA biomarkers in liquid-based cytology and plasma for early detection of high-grade cervical intraepithelial neoplasia
Presenter: Stéphanie Calfa
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - Integrated proteogenomic approach for discovering potential biomarkers in urothelial carcinoma of the bladder
Presenter: PONGSAKORN CHOOCHUEN
Session: Cocktail & Poster Display session
Resources:
Abstract